THOR methylation as a pan-cancer mechanism of TERT activation: toward a clinically relevant epigenetic biomarker - Top-Institutions - MDSpire

THOR methylation as a pan-cancer mechanism of TERT activation: toward a clinically relevant epigenetic biomarker

  • By

  • Alain Chebly

  • Edith Chevret

  • July 17, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Princess Margaret Cancer Centre, University Health Network
    Princess Margaret Cancer Centre, University Health Network

    Toronto, Ontario

    Key Differentiators

    • Oncology

  • #2

    Duke Cancer Institute
    Duke Cancer Institute

    Durham, North Carolina

    Key Differentiators

    • Oncology

Original Source(s)

THOR methylation as a pan-cancer mechanism of TERT activation: toward a clinically relevant epigenetic biomarker

  • by Alain Chebly, Edith Chevret

  • July 17, 2026

Related Content

Intratumoral and intracranial hemorrhage associated with MAPK-pathway targeted therapy: a systematic review and mechanistic synthesis

Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients

Intravascular large B-cell lymphoma masked by multinodular goiter of the thyroid: a case report and diagnostic pitfall